Global

Will changes to the P&R system in the UK finally put some real metrics behind the elusive concept of value?

In just the past few years, South Africa has hit several key economic benchmarks demonstrating the country's upward trajectory.

Pharma companies entering the emerging markets are under pressure to offer a convincing Corporate Value Proposition (CVP).

Pharm Exec talks to Carlos Plata, Chief Scientific Officer of Esteve, the Spanish company that is rising above the economic gloom to become a major player in pain.

What does a Scottish vote for independence mean for Big Pharma investment and healthcare funding and delivery in the UK?

India's most prominent scientist, Dr R.A. Mashelkar, President of the Global Research Alliance, on delivering medicines profitably but cheaply to low income countries.

Despite the severe blow to its economy, Ukraine has been recovering at a faster rate than its Western European counterparts

Manufacturers, wholesalers, pharmacists and even parallel importers are uniting under a common blanket, writes Reflector.

With growth as its guiding light, Novartis has big plans for the emerging markets. Pharm Exec sits down with CEO Joe Jimenez to understand what it will take the company to best the competition.

After his predecessor and countryman left the EMA in disgrace, Guido Rasi jumps in as executive director-with great challenges ahead.

Simon Estcourt assesses how the regulatory landscape for managed access programs is evolving, particularly in the UK.

China's healthcare reforms are generating uncertainty for its domestic pharmaceutical market, writes Jon Zifferblatt.

Guido Rasi, the European Medicine Association's new executive director, faces many challenges, says Reflector, not least shaking off the legacy of his early predecessor, Duilio Poggiolini.

With the $12-billion valued Indian pharma industry expected to grow at a CAGR of 16%, the Indian government plans to capitalize on the growth potential in an effort to beat the competition.

Brazil's clinical trial research is the country's backbone.

Brazil was the last country to enter the fiscal crisis, but also the first to exit. And with a burgeoning middle class and a staunch commitment to national development, its pharmaceutical future is now.

Brazilian industry is learning to spread its pharma manufacturing around more.

Astellas makes its presence felt in Brazil.

French-based Besins is a relatively new entrant to the Brazilian pharma market.

With Europe's economic troubles causing domestic profitability concerns, established pharmaceutical companies may need look to emerging markets for outsourcing partners.

The EU's Innovative Medicines Initiative is helping to invigorate new drug development, but there are still many hurdles to tackle before its promise is realized.

Torrent's affiliate in Brazil has become the India-based company's biggest.

Biominas helps foster the development of biotech-related businesses in Brazil.

Hungary's high-quality infrsatructure, highly skilled labor force, and central geographic location have turned the country into an attractive destination for investment.

William Looney looks at how Big Pharma is attempting to bridge the emerging markets' widening cancer divide.